Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
Calcification of thoracic aorta - solar eclipse sign.

Cases journal

Dhoble A, Puttarajappa C.
PMID: 18759981
Cases J. 2008 Aug 29;1(1):133. doi: 10.1186/1757-1626-1-133.

BACKGROUND: Calcification of thoracic aorta is very common in old people, especially ones with hypertension. This can sometime be visible on plain chest radiograph.CASE PRESENTATION: We present a case of a male patient who had extensive deposition of calcium...

Cite
Dhoble A, Puttarajappa C. Calcification of thoracic aorta - solar eclipse sign. Cases J. 2008;1(1):133doi: 10.1186/1757-1626-1-133.
Dhoble, A., & Puttarajappa, C. (2008). Calcification of thoracic aorta - solar eclipse sign. Cases journal, 1(1), 133. https://doi.org/10.1186/1757-1626-1-133
Dhoble, Abhijeet, and Puttarajappa, Chethan. "Calcification of thoracic aorta - solar eclipse sign." Cases journal vol. 1,1 (2008): 133. doi: https://doi.org/10.1186/1757-1626-1-133
Dhoble A, Puttarajappa C. Calcification of thoracic aorta - solar eclipse sign. Cases J. 2008 Aug 29;1(1):133. doi: 10.1186/1757-1626-1-133. PMID: 18759981; PMCID: PMC2546373.
Copy Download .nbib Format: NLM
Antibody-mediated rejection in kidney transplantation: a review.

Journal of transplantation

Puttarajappa C, Shapiro R, Tan HP.
PMID: 22577514
J Transplant. 2012;2012:193724. doi: 10.1155/2012/193724. Epub 2012 Apr 10.

Antibody mediated rejection (AMR) poses a significant and continued challenge for long term graft survival in kidney transplantation. However, in the recent years, there has emerged an increased understanding of the varied manifestations of the antibody mediated processes in...

Cite
Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review. J Transplant. 2012;2012:193724doi: 10.1155/2012/193724.
Puttarajappa, C., Shapiro, R., & Tan, H. P. (2012). Antibody-mediated rejection in kidney transplantation: a review. Journal of transplantation, 2012193724. https://doi.org/10.1155/2012/193724
Puttarajappa, Chethan, et al. "Antibody-mediated rejection in kidney transplantation: a review." Journal of transplantation vol. 2012 (2012): 193724. doi: https://doi.org/10.1155/2012/193724
Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review. J Transplant. 2012;2012:193724. doi: 10.1155/2012/193724. Epub 2012 Apr 10. PMID: 22577514; PMCID: PMC3337620.
Copy Download .nbib Format: NLM
Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?.

Transplantation direct

Ng YH, Litvinovich I, Leyva Y, Ford CG, Zhu Y, Kendall K, Croswell E, Puttarajappa CM, Amanda Dew M, Shapiro R, Unruh ML, Myaskovsky L.
PMID: 34912945
Transplant Direct. 2021 Dec 13;8(1):e1256. doi: 10.1097/TXD.0000000000001256. eCollection 2022 Jan.

BACKGROUND: Barriers to medication adherence may differ from barriers in other domains of adherence. In this study, we assessed the association between pre-kidney transplantation (KT) factors with nonadherent behaviors in 3 different domains post-KT.METHODS: We conducted a prospective cohort...

Cite
Ng YH, Litvinovich I, Leyva Y, et al. Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?. Transplant Direct. 2021;8(1):e1256doi: 10.1097/TXD.0000000000001256.
Ng, Y. H., Litvinovich, I., Leyva, Y., Ford, C. G., Zhu, Y., Kendall, K., Croswell, E., Puttarajappa, C. M., Amanda Dew, M., Shapiro, R., Unruh, M. L., & Myaskovsky, L. (2022). Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?. Transplantation direct, 8(1), e1256. https://doi.org/10.1097/TXD.0000000000001256
Ng, Yue-Harn, et al. "Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?." Transplantation direct vol. 8,1 (2022): e1256. doi: https://doi.org/10.1097/TXD.0000000000001256
Ng YH, Litvinovich I, Leyva Y, Ford CG, Zhu Y, Kendall K, Croswell E, Puttarajappa CM, Amanda Dew M, Shapiro R, Unruh ML, Myaskovsky L. Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?. Transplant Direct. 2021 Dec 13;8(1):e1256. doi: 10.1097/TXD.0000000000001256. eCollection 2022 Jan. PMID: 34912945; PMCID: PMC8670587.
Copy Download .nbib Format: NLM
Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation.

Clinical transplantation

Mehta RB, Shimko K, Zhang X, Puttarajappa C, Wu C, Sharma A, Molinari M, Tevar AD, Hariharan S, Sood P.
PMID: 35000234
Clin Transplant. 2022 Jan 09;e14582. doi: 10.1111/ctr.14582. Epub 2022 Jan 09.

Antithymocyte globulin (ATG) is a commonly used induction agent in kidney transplant recipients. However, the optimal dosing has not been well defined. Our protocol aims for a 5-6 mg/kg cumulative dose. It is unclear if a dose lower than...

Cite
Mehta RB, Shimko K, Zhang X, et al. Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation. Clin Transplant. 2022;e14582doi: 10.1111/ctr.14582.
Mehta, R. B., Shimko, K., Zhang, X., Puttarajappa, C., Wu, C., Sharma, A., Molinari, M., Tevar, A. D., Hariharan, S., & Sood, P. (2022). Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation. Clinical transplantation, e14582. https://doi.org/10.1111/ctr.14582
Mehta, Rajil B, et al. "Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation." Clinical transplantation vol. (2022): e14582. doi: https://doi.org/10.1111/ctr.14582
Mehta RB, Shimko K, Zhang X, Puttarajappa C, Wu C, Sharma A, Molinari M, Tevar AD, Hariharan S, Sood P. Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation. Clin Transplant. 2022 Jan 09;e14582. doi: 10.1111/ctr.14582. Epub 2022 Jan 09. PMID: 35000234.
Copy Download .nbib Format: NLM
Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation.

Transplantation direct

Puttarajappa CM, Hariharan S, Humar A, Paliwal Y, Gao X, Cruz RJ, Ganoza AJ, Landsittel D, Bhattarai M, Sogawa H.
PMID: 30255137
Transplant Direct. 2018 Jul 20;4(8):e377. doi: 10.1097/TXD.0000000000000815. eCollection 2018 Aug.

BACKGROUND: Data on dialysis and renal transplantation (RT) after intestinal transplantation (IT) are sparse. Whether changes in immunosuppression and surgical techniques have modified these outcomes is unknown.METHODS: Two hundred eighty-eight adult intestinal transplants performed between 1990 and 2014 at...

Cite
Puttarajappa CM, Hariharan S, Humar A, et al. Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation. Transplant Direct. 2018;4(8):e377doi: 10.1097/TXD.0000000000000815.
Puttarajappa, C. M., Hariharan, S., Humar, A., Paliwal, Y., Gao, X., Cruz, R. J., Ganoza, A. J., Landsittel, D., Bhattarai, M., & Sogawa, H. (2018). Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation. Transplantation direct, 4(8), e377. https://doi.org/10.1097/TXD.0000000000000815
Puttarajappa, Chethan M, et al. "Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation." Transplantation direct vol. 4,8 (2018): e377. doi: https://doi.org/10.1097/TXD.0000000000000815
Puttarajappa CM, Hariharan S, Humar A, Paliwal Y, Gao X, Cruz RJ, Ganoza AJ, Landsittel D, Bhattarai M, Sogawa H. Outcomes of Adult Intestinal Transplant Recipients Requiring Dialysis and Renal Transplantation. Transplant Direct. 2018 Jul 20;4(8):e377. doi: 10.1097/TXD.0000000000000815. eCollection 2018 Aug. PMID: 30255137; PMCID: PMC6092176.
Copy Download .nbib Format: NLM
Robotic Versus Open Renal Transplantation in Obese Patients: Protocol for a Cost-Benefit Markov Model Analysis.

JMIR research protocols

Molinari M, Puttarajappa C, Wijkstrom M, Ganoza A, Lopez R, Tevar A.
PMID: 29519780
JMIR Res Protoc. 2018 Mar 08;7(3):e74. doi: 10.2196/resprot.8294.

BACKGROUND: Recent studies have reported a significant decrease in wound problems and hospital stay in obese patients undergoing renal transplantation by robotic-assisted minimally invasive techniques with no difference in graft function.OBJECTIVE: Due to the lack of cost-benefit studies on...

Cite
Molinari M, Puttarajappa C, Wijkstrom M, et al. Robotic Versus Open Renal Transplantation in Obese Patients: Protocol for a Cost-Benefit Markov Model Analysis. JMIR Res Protoc. 2018;7(3):e74doi: 10.2196/resprot.8294.
Molinari, M., Puttarajappa, C., Wijkstrom, M., Ganoza, A., Lopez, R., & Tevar, A. (2018). Robotic Versus Open Renal Transplantation in Obese Patients: Protocol for a Cost-Benefit Markov Model Analysis. JMIR research protocols, 7(3), e74. https://doi.org/10.2196/resprot.8294
Molinari, Michele, et al. "Robotic Versus Open Renal Transplantation in Obese Patients: Protocol for a Cost-Benefit Markov Model Analysis." JMIR research protocols vol. 7,3 (2018): e74. doi: https://doi.org/10.2196/resprot.8294
Molinari M, Puttarajappa C, Wijkstrom M, Ganoza A, Lopez R, Tevar A. Robotic Versus Open Renal Transplantation in Obese Patients: Protocol for a Cost-Benefit Markov Model Analysis. JMIR Res Protoc. 2018 Mar 08;7(3):e74. doi: 10.2196/resprot.8294. PMID: 29519780; PMCID: PMC5865002.
Copy Download .nbib Format: NLM
Kidney Transplant Outcomes After Primary, Repeat and Kidney After Nonrenal Solid Organ Transplantation: A Single-Center Experience.

Transplantation direct

Sood P, Gao X, Mehta R, Landsittel D, Wu C, Nusrat R, Puttarajappa C, Tevar AD, Hariharan S.
PMID: 27500265
Transplant Direct. 2016 May 04;2(6):e75. doi: 10.1097/TXD.0000000000000586. eCollection 2016 Jun.

BACKGROUND: Improvements in renal allograft outcomes have permitted kidney transplantation after prior kidney allograft failure as well as after nonrenal solid organ transplantation. This study compares renal allograft outcomes in the 3 groups, that is, primary, repeat, and kidney...

Cite
Sood P, Gao X, Mehta R, et al. Kidney Transplant Outcomes After Primary, Repeat and Kidney After Nonrenal Solid Organ Transplantation: A Single-Center Experience. Transplant Direct. 2016;2(6):e75doi: 10.1097/TXD.0000000000000586.
Sood, P., Gao, X., Mehta, R., Landsittel, D., Wu, C., Nusrat, R., Puttarajappa, C., Tevar, A. D., & Hariharan, S. (2016). Kidney Transplant Outcomes After Primary, Repeat and Kidney After Nonrenal Solid Organ Transplantation: A Single-Center Experience. Transplantation direct, 2(6), e75. https://doi.org/10.1097/TXD.0000000000000586
Sood, Puneet, et al. "Kidney Transplant Outcomes After Primary, Repeat and Kidney After Nonrenal Solid Organ Transplantation: A Single-Center Experience." Transplantation direct vol. 2,6 (2016): e75. doi: https://doi.org/10.1097/TXD.0000000000000586
Sood P, Gao X, Mehta R, Landsittel D, Wu C, Nusrat R, Puttarajappa C, Tevar AD, Hariharan S. Kidney Transplant Outcomes After Primary, Repeat and Kidney After Nonrenal Solid Organ Transplantation: A Single-Center Experience. Transplant Direct. 2016 May 04;2(6):e75. doi: 10.1097/TXD.0000000000000586. eCollection 2016 Jun. PMID: 27500265; PMCID: PMC4946525.
Copy Download .nbib Format: NLM
Severe Hyponatremia and Continuous Renal Replacement Therapy: Safety and Effectiveness of Low-Sodium Dialysate.

Kidney medicine

Tandukar S, Kim C, Kalra K, Verma S, Palevsky PM, Puttarajappa C.
PMID: 32775984
Kidney Med. 2020 Jun 15;2(4):437-449. doi: 10.1016/j.xkme.2020.05.007. eCollection 2020.

RATIONALE & OBJECTIVE: In patients with severe hyponatremia in the setting of acute kidney injury or end-stage kidney disease, continuous renal replacement therapy (CRRT) using standard-sodium (140 mEq/L) fluids may lead to excessively rapid correction of plasma sodium concentration....

Cite
Tandukar S, Kim C, Kalra K, et al. Severe Hyponatremia and Continuous Renal Replacement Therapy: Safety and Effectiveness of Low-Sodium Dialysate. Kidney Med. 2020;2(4):437-449doi: 10.1016/j.xkme.2020.05.007.
Tandukar, S., Kim, C., Kalra, K., Verma, S., Palevsky, P. M., & Puttarajappa, C. (2020). Severe Hyponatremia and Continuous Renal Replacement Therapy: Safety and Effectiveness of Low-Sodium Dialysate. Kidney medicine, 2(4), 437-449. https://doi.org/10.1016/j.xkme.2020.05.007
Tandukar, Srijan, et al. "Severe Hyponatremia and Continuous Renal Replacement Therapy: Safety and Effectiveness of Low-Sodium Dialysate." Kidney medicine vol. 2,4 (2020): 437-449. doi: https://doi.org/10.1016/j.xkme.2020.05.007
Tandukar S, Kim C, Kalra K, Verma S, Palevsky PM, Puttarajappa C. Severe Hyponatremia and Continuous Renal Replacement Therapy: Safety and Effectiveness of Low-Sodium Dialysate. Kidney Med. 2020 Jun 15;2(4):437-449. doi: 10.1016/j.xkme.2020.05.007. eCollection 2020. PMID: 32775984; PMCID: PMC7406832.
Copy Download .nbib Format: NLM
Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?.

Transplantation direct

Ng YH, Litvinovich I, Leyva Y, Ford CG, Zhu Y, Kendall K, Croswell E, Puttarajappa CM, Amanda Dew M, Shapiro R, Unruh ML, Myaskovsky L.
PMID: 34912945
Transplant Direct. 2021 Dec 13;8(1):e1256. doi: 10.1097/TXD.0000000000001256. eCollection 2022 Jan.

BACKGROUND: Barriers to medication adherence may differ from barriers in other domains of adherence. In this study, we assessed the association between pre-kidney transplantation (KT) factors with nonadherent behaviors in 3 different domains post-KT.METHODS: We conducted a prospective cohort...

Cite
Ng YH, Litvinovich I, Leyva Y, et al. Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?. Transplant Direct. 2021;8(1):e1256doi: 10.1097/TXD.0000000000001256.
Ng, Y. H., Litvinovich, I., Leyva, Y., Ford, C. G., Zhu, Y., Kendall, K., Croswell, E., Puttarajappa, C. M., Amanda Dew, M., Shapiro, R., Unruh, M. L., & Myaskovsky, L. (2022). Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?. Transplantation direct, 8(1), e1256. https://doi.org/10.1097/TXD.0000000000001256
Ng, Yue-Harn, et al. "Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?." Transplantation direct vol. 8,1 (2022): e1256. doi: https://doi.org/10.1097/TXD.0000000000001256
Ng YH, Litvinovich I, Leyva Y, Ford CG, Zhu Y, Kendall K, Croswell E, Puttarajappa CM, Amanda Dew M, Shapiro R, Unruh ML, Myaskovsky L. Medication, Healthcare Follow-up, and Lifestyle Nonadherence: Do They Share the Same Risk Factors?. Transplant Direct. 2021 Dec 13;8(1):e1256. doi: 10.1097/TXD.0000000000001256. eCollection 2022 Jan. PMID: 34912945; PMCID: PMC8670587.
Copy Download .nbib Format: NLM
Reversal of Roux-en-Y Gastric Bypass for Successful Salvage of Renal Allograft.

The American surgeon

Hrebinko K, Moroni E, Ganoza A, Puttarajappa CM, Molinari M, Sood P, El Hag M, Wijkstrom M, Tevar AD.
PMID: 33631945
Am Surg. 2021 Feb 26;3134821998674. doi: 10.1177/0003134821998674. Epub 2021 Feb 26.

Enteric hyperoxaluria (EH) is a known complication of Roux-en-Y gastric bypass (RYGB) and can lead to nephrolithiasis, oxalate-induced nephropathy, and end-stage renal disease. Recurrent EH-induced renal impairment has been reported after kidney transplantation and may lead to allograft loss....

Cite
Hrebinko K, Moroni E, Ganoza A, et al. Reversal of Roux-en-Y Gastric Bypass for Successful Salvage of Renal Allograft. Am Surg. 2021;3134821998674doi: 10.1177/0003134821998674.
Hrebinko, K., Moroni, E., Ganoza, A., Puttarajappa, C. M., Molinari, M., Sood, P., El Hag, M., Wijkstrom, M., & Tevar, A. D. (2021). Reversal of Roux-en-Y Gastric Bypass for Successful Salvage of Renal Allograft. The American surgeon, 3134821998674. https://doi.org/10.1177/0003134821998674
Hrebinko, Katherine, et al. "Reversal of Roux-en-Y Gastric Bypass for Successful Salvage of Renal Allograft." The American surgeon vol. (2021): 3134821998674. doi: https://doi.org/10.1177/0003134821998674
Hrebinko K, Moroni E, Ganoza A, Puttarajappa CM, Molinari M, Sood P, El Hag M, Wijkstrom M, Tevar AD. Reversal of Roux-en-Y Gastric Bypass for Successful Salvage of Renal Allograft. Am Surg. 2021 Feb 26;3134821998674. doi: 10.1177/0003134821998674. Epub 2021 Feb 26. PMID: 33631945.
Copy Download .nbib Format: NLM
Dermatomyositis and supraventricular tachycardia.

International archives of medicine

Dhoble A, Puttarajappa C, Neiberg A.
PMID: 19014529
Int Arch Med. 2008 Nov 13;1(1):25. doi: 10.1186/1755-7682-1-25.

BACKGROUND: Dermatomyositis is an idiopathic inflammatory myopathy, often associated with an underlying malignancy. Its prevalence rate is approximately one per 100,000 in the general population, and is even rarer without evidence of a cancer. Dermatomyositis rarely involves myocardial muscle...

Cite
Dhoble A, Puttarajappa C, Neiberg A. Dermatomyositis and supraventricular tachycardia. Int Arch Med. 2008;1(1):25doi: 10.1186/1755-7682-1-25.
Dhoble, A., Puttarajappa, C., & Neiberg, A. (2008). Dermatomyositis and supraventricular tachycardia. International archives of medicine, 1(1), 25. https://doi.org/10.1186/1755-7682-1-25
Dhoble, Abhijeet, et al. "Dermatomyositis and supraventricular tachycardia." International archives of medicine vol. 1,1 (2008): 25. doi: https://doi.org/10.1186/1755-7682-1-25
Dhoble A, Puttarajappa C, Neiberg A. Dermatomyositis and supraventricular tachycardia. Int Arch Med. 2008 Nov 13;1(1):25. doi: 10.1186/1755-7682-1-25. PMID: 19014529; PMCID: PMC2588571.
Copy Download .nbib Format: NLM
Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation.

Clinical transplantation

Mehta RB, Shimko K, Zhang X, Puttarajappa C, Wu C, Sharma A, Molinari M, Tevar AD, Hariharan S, Sood P.
PMID: 35000234
Clin Transplant. 2022 Jan 09;e14582. doi: 10.1111/ctr.14582. Epub 2022 Jan 09.

Antithymocyte globulin (ATG) is a commonly used induction agent in kidney transplant recipients. However, the optimal dosing has not been well defined. Our protocol aims for a 5-6 mg/kg cumulative dose. It is unclear if a dose lower than...

Cite
Mehta RB, Shimko K, Zhang X, et al. Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation. Clin Transplant. 2022;e14582doi: 10.1111/ctr.14582.
Mehta, R. B., Shimko, K., Zhang, X., Puttarajappa, C., Wu, C., Sharma, A., Molinari, M., Tevar, A. D., Hariharan, S., & Sood, P. (2022). Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation. Clinical transplantation, e14582. https://doi.org/10.1111/ctr.14582
Mehta, Rajil B, et al. "Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation." Clinical transplantation vol. (2022): e14582. doi: https://doi.org/10.1111/ctr.14582
Mehta RB, Shimko K, Zhang X, Puttarajappa C, Wu C, Sharma A, Molinari M, Tevar AD, Hariharan S, Sood P. Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation. Clin Transplant. 2022 Jan 09;e14582. doi: 10.1111/ctr.14582. Epub 2022 Jan 09. PMID: 35000234.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries